EODData

MEMBERSHIP REGISTER LOG IN

NYSE, RFL: Rafael Holdings Inc

24 Nov 25 15:59
LAST:

1.235

CHANGE:
 0.01		OPEN:
1.240		HIGH:
1.240		ASK:
0.000		VOLUME:
36.1K
CHG(%):
0.40		PREV:
1.240		LOW:
1.220		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
24 Nov 251.2401.2401.2201.23536.1K
21 Nov 251.2801.2801.1901.24067.9K
20 Nov 251.2701.2801.2001.24069.2K
19 Nov 251.2701.2801.1901.24037.5K
18 Nov 251.2001.2501.1901.230122.6K
17 Nov 251.2301.2901.2001.220106.3K
14 Nov 251.2401.2801.2001.220318.0K
13 Nov 251.2701.3001.2401.260174.5K
12 Nov 251.2601.2901.2601.27055.0K
11 Nov 251.2901.3201.2611.27017.0K

PROFILE

Name:Rafael Holdings Inc
About:Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), a stable analog of transient, acylated catalytic intermediates of lipoate currently under phase 2 open-label multi-cohort study evaluating CPI-613 in combination with hydroxychloroquine and 5-fluorouracil or gemcitabine in patients with advanced chemorefractory colorectal, pancreatic, or other solid cancers; and under phase 1 dose-escalation study of CPI-613 in combination with chemoradiation in patients with pancreatic adenocarcinoma. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
Sector:Real Estate
Address:520 Broad Street, Newark, NJ, United States, 07102
Website:https://www.rafaelholdings.com
CUSIP:75062E106
CIK:0001713863
ISIN:US75062E1064
FIGI:BBG00J3YYS92

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:14.30 
PEG Ratio:-0.17 
Price to Sales:96.19 
Price to Book:0.54 
Profit Margin:0.76 
Operating Margin:-16.33 
Return on Assets:-0.10 
Return on Equity:-0.27 
EPS Ratio:-0.92 
Revenue:732.0K 
Shares:34.3M 
Market Cap:42.36M 

TECHNICAL INDICATORS

MA5:1.240.2%
MA10:1.240.6%
MA20:1.294.1%
MA50:1.348.7%
MA100:1.5324.1%
MA200:1.6432.6%
STO9:18.75 
STO14:10.71 
RSI14:19.35 
WPR14:-86.36 
MTM14:-0.10
ROC14:-0.07 
ATR:0.06 
Week High:1.294.5%
Week Low:1.193.8%
Month High:1.3811.7%
Month Low:1.1932.6%
Year High:3.19158.3%
Year Low:1.193.8%
Volatility:29.41 

RECENT SPLITS

Date Ratio
09 May 20251014-1000

RECENT DIVIDENDS

Date Amount
19 May 2010$12.82
18 Dec 2009$0.02
19 Jun 2009$0.01
20 Mar 2009$0.02
19 Dec 2008$0.14
19 Sep 2008$0.16